Osteoporosis News

LAS VEGAS — Patients taking bisphosphonates were not at increased risk for developing esophageal cancer in a recent study presented at the 2012 American College of Gastroenterology Annual Scientific Meeting.

Investigators at University of California, Los Angeles, have developed a new method to assess the risks of osteoporosis and fracture in women using bone mineral density measures with body size and bone size to create composite bone strength indices without racial or ethnic background information.

Following treatment for a fracture in clinics or hospitals, 80% of patients are not screened for their risk of osteoporosis or falls, which could lead to future fractures, pain, disability and other complications, according to report released by the International Osteoporosis Foundation.

In Australia, the uptake of bisphosphonates and the rollout of public health campaigns and strategies that address osteoporosis may have led to a decrease in the age-standardized incidence of osteoporotic hip fracture, according to recent study results.

Older men with an accelerated femoral neck bone mineral density loss have increased risk for hip and other non-spine fractures, according to this study.

Denosumab increases bone formation and decreases the number of giant cells by 90% in patients with giant-cell tumor of the bone. Additionally, the drug may be useful in the treatment of patients with giant-cell tumor of the bone (GCTB) who surgeons may otherwise choose to recommend for joint replacement procedures, according to researchers from California.

Abstinence from alcohol for as little as 8 weeks may reduce an imbalance between bone formation and resorption, while exercise can provide a protective barrier for bone loss, according to researchers from Austria.

When patients comply with osteoporosis treatment for at least 6 months, their response to treatment can be identified by the number of fractures, the changes in bone turnover markers, and any changes in bone mineral density they have, according to a recent International Osteoporosis Foundation position paper.

In a 2-year randomized study with a 2-year open -label extension, osteoporotic men who received risedronate once weekly for 2 years had similar results with the regimen as those who took the same dose of risedronate over 4 years, according to recent study results.

Premenopausal women who exercise more than 2 hours per day are more likely to have increased bone health over sedentary women, according to recent study by investigators in Saudi Arabia.